Talha Badar and Francesca Palandri/LinkedIn
Jun 12, 2026, 16:13
Talha Badar: Excellent Talk by Francesca Palandri on ET and PV at EHA 2026
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, shared a post on X:
“Excellent talk by Dr. Francesca Palandri on ET and PV at EHA 2026
Key takeaways:
Hydroxyurea remains the main 1st-line cytoreductive therapy, but care is increasingly individualized.
Emerging directions:
- Hepcidin modulation in PV, rusfertide and TMPRSS6 inhibitors
- CALR-targeted therapy, mAb and bispecific T-cell engagers
- Multidisciplinary care, including CV risk, fertility, dermatology, thrombosis, QoL
The future of MPN care is moving beyond count control toward disease biology, iron regulation, immune targeting, and patient-centered care.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation